Cell origins of high-grade serous ovarian cancer

Jaeyeon Kim, Eun Young Park, Olga Kim, Jeanne Schilder, Donna M. Coffey, Chi Heum Cho, Robert C. Bast

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates that STIC may serve as a precursor for HGSC in high-risk women carrying germline BRCA1 or 2 mutations. Yet not all STIC lesions appear to progress to clinical HGSCs, nor would all HGSCs arise from STIC lesions, even in high-risk women. Moreover, the clinical importance of STIC remains less clear in women in the general population, in which 85–90% of all HGSCs arise. Recently, increasing attention has been brought to the possibility that many potential precursor or premalignant lesions, though composed of microscopically—and genetically—cancerous cells, do not advance to malignant tumors or lethal malignancies. Hence, rigorous causal evidence would be crucial to establish that STIC is a bona fide premalignant lesion for metastatic HGSC. While not all STICs may transform into malignant tumors, these lesions are clearly associated with increased risk for HGSC. Identification of the molecular characteristics of STICs that predict their malignant potential and clinical behavior would bolster the clinical importance of STIC. Also, as STIC lesions alone cannot account for all HGSCs, other potential cellular origins of HGSC need to be investigated. The fallopian tube stroma in mice, for instance, has been shown to be capable of giving rise to metastatic HGSC, which faithfully recapitulates the clinical behavior and molecular aspect of human HGSC. Elucidating the precise cell(s) of origin of HGSC will be critical for improving the early detection and prevention of ovarian cancer, ultimately reducing ovarian cancer mortality.

Original languageEnglish (US)
Article number433
JournalCancers
Volume10
Issue number11
DOIs
StatePublished - Nov 12 2018

Fingerprint

Ovarian Neoplasms
Carcinoma in Situ
Carcinoma
Fallopian Tubes
Epithelium
Peritoneum
Ovary
Neoplasms

Keywords

  • Epithelial ovarian cancer
  • Fallopian tube
  • High-grade serous carcinoma (HGSC)
  • High-grade serous ovarian cancer (HGSOC)
  • Ovarian cancer
  • Ovarian cancer origin
  • Ovarian surface epithelium (OSE)
  • Serous tubal intraepithelial carcinoma (STIC)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kim, J., Park, E. Y., Kim, O., Schilder, J., Coffey, D. M., Cho, C. H., & Bast, R. C. (2018). Cell origins of high-grade serous ovarian cancer. Cancers, 10(11), [433]. https://doi.org/10.3390/cancers10110433

Cell origins of high-grade serous ovarian cancer. / Kim, Jaeyeon; Park, Eun Young; Kim, Olga; Schilder, Jeanne; Coffey, Donna M.; Cho, Chi Heum; Bast, Robert C.

In: Cancers, Vol. 10, No. 11, 433, 12.11.2018.

Research output: Contribution to journalReview article

Kim, J, Park, EY, Kim, O, Schilder, J, Coffey, DM, Cho, CH & Bast, RC 2018, 'Cell origins of high-grade serous ovarian cancer', Cancers, vol. 10, no. 11, 433. https://doi.org/10.3390/cancers10110433
Kim J, Park EY, Kim O, Schilder J, Coffey DM, Cho CH et al. Cell origins of high-grade serous ovarian cancer. Cancers. 2018 Nov 12;10(11). 433. https://doi.org/10.3390/cancers10110433
Kim, Jaeyeon ; Park, Eun Young ; Kim, Olga ; Schilder, Jeanne ; Coffey, Donna M. ; Cho, Chi Heum ; Bast, Robert C. / Cell origins of high-grade serous ovarian cancer. In: Cancers. 2018 ; Vol. 10, No. 11.
@article{27053d95831549d88e147cf20e1743a2,
title = "Cell origins of high-grade serous ovarian cancer",
abstract = "High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates that STIC may serve as a precursor for HGSC in high-risk women carrying germline BRCA1 or 2 mutations. Yet not all STIC lesions appear to progress to clinical HGSCs, nor would all HGSCs arise from STIC lesions, even in high-risk women. Moreover, the clinical importance of STIC remains less clear in women in the general population, in which 85–90{\%} of all HGSCs arise. Recently, increasing attention has been brought to the possibility that many potential precursor or premalignant lesions, though composed of microscopically—and genetically—cancerous cells, do not advance to malignant tumors or lethal malignancies. Hence, rigorous causal evidence would be crucial to establish that STIC is a bona fide premalignant lesion for metastatic HGSC. While not all STICs may transform into malignant tumors, these lesions are clearly associated with increased risk for HGSC. Identification of the molecular characteristics of STICs that predict their malignant potential and clinical behavior would bolster the clinical importance of STIC. Also, as STIC lesions alone cannot account for all HGSCs, other potential cellular origins of HGSC need to be investigated. The fallopian tube stroma in mice, for instance, has been shown to be capable of giving rise to metastatic HGSC, which faithfully recapitulates the clinical behavior and molecular aspect of human HGSC. Elucidating the precise cell(s) of origin of HGSC will be critical for improving the early detection and prevention of ovarian cancer, ultimately reducing ovarian cancer mortality.",
keywords = "Epithelial ovarian cancer, Fallopian tube, High-grade serous carcinoma (HGSC), High-grade serous ovarian cancer (HGSOC), Ovarian cancer, Ovarian cancer origin, Ovarian surface epithelium (OSE), Serous tubal intraepithelial carcinoma (STIC)",
author = "Jaeyeon Kim and Park, {Eun Young} and Olga Kim and Jeanne Schilder and Coffey, {Donna M.} and Cho, {Chi Heum} and Bast, {Robert C.}",
year = "2018",
month = "11",
day = "12",
doi = "10.3390/cancers10110433",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Cell origins of high-grade serous ovarian cancer

AU - Kim, Jaeyeon

AU - Park, Eun Young

AU - Kim, Olga

AU - Schilder, Jeanne

AU - Coffey, Donna M.

AU - Cho, Chi Heum

AU - Bast, Robert C.

PY - 2018/11/12

Y1 - 2018/11/12

N2 - High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates that STIC may serve as a precursor for HGSC in high-risk women carrying germline BRCA1 or 2 mutations. Yet not all STIC lesions appear to progress to clinical HGSCs, nor would all HGSCs arise from STIC lesions, even in high-risk women. Moreover, the clinical importance of STIC remains less clear in women in the general population, in which 85–90% of all HGSCs arise. Recently, increasing attention has been brought to the possibility that many potential precursor or premalignant lesions, though composed of microscopically—and genetically—cancerous cells, do not advance to malignant tumors or lethal malignancies. Hence, rigorous causal evidence would be crucial to establish that STIC is a bona fide premalignant lesion for metastatic HGSC. While not all STICs may transform into malignant tumors, these lesions are clearly associated with increased risk for HGSC. Identification of the molecular characteristics of STICs that predict their malignant potential and clinical behavior would bolster the clinical importance of STIC. Also, as STIC lesions alone cannot account for all HGSCs, other potential cellular origins of HGSC need to be investigated. The fallopian tube stroma in mice, for instance, has been shown to be capable of giving rise to metastatic HGSC, which faithfully recapitulates the clinical behavior and molecular aspect of human HGSC. Elucidating the precise cell(s) of origin of HGSC will be critical for improving the early detection and prevention of ovarian cancer, ultimately reducing ovarian cancer mortality.

AB - High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates that STIC may serve as a precursor for HGSC in high-risk women carrying germline BRCA1 or 2 mutations. Yet not all STIC lesions appear to progress to clinical HGSCs, nor would all HGSCs arise from STIC lesions, even in high-risk women. Moreover, the clinical importance of STIC remains less clear in women in the general population, in which 85–90% of all HGSCs arise. Recently, increasing attention has been brought to the possibility that many potential precursor or premalignant lesions, though composed of microscopically—and genetically—cancerous cells, do not advance to malignant tumors or lethal malignancies. Hence, rigorous causal evidence would be crucial to establish that STIC is a bona fide premalignant lesion for metastatic HGSC. While not all STICs may transform into malignant tumors, these lesions are clearly associated with increased risk for HGSC. Identification of the molecular characteristics of STICs that predict their malignant potential and clinical behavior would bolster the clinical importance of STIC. Also, as STIC lesions alone cannot account for all HGSCs, other potential cellular origins of HGSC need to be investigated. The fallopian tube stroma in mice, for instance, has been shown to be capable of giving rise to metastatic HGSC, which faithfully recapitulates the clinical behavior and molecular aspect of human HGSC. Elucidating the precise cell(s) of origin of HGSC will be critical for improving the early detection and prevention of ovarian cancer, ultimately reducing ovarian cancer mortality.

KW - Epithelial ovarian cancer

KW - Fallopian tube

KW - High-grade serous carcinoma (HGSC)

KW - High-grade serous ovarian cancer (HGSOC)

KW - Ovarian cancer

KW - Ovarian cancer origin

KW - Ovarian surface epithelium (OSE)

KW - Serous tubal intraepithelial carcinoma (STIC)

UR - http://www.scopus.com/inward/record.url?scp=85057199902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057199902&partnerID=8YFLogxK

U2 - 10.3390/cancers10110433

DO - 10.3390/cancers10110433

M3 - Review article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

M1 - 433

ER -